123 related articles for article (PubMed ID: 23524088)
1. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1).
Voss MD; Zoller G; Matter H; Herling AW; Biemer-Daub G; Pfenninger A; Haag-Diergarten S; Keil S; Kohlmann M; Schmidts HL
Eur J Pharmacol; 2013 May; 707(1-3):140-6. PubMed ID: 23524088
[TBL] [Abstract][Full Text] [Related]
2. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
3. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
[TBL] [Abstract][Full Text] [Related]
4. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
[TBL] [Abstract][Full Text] [Related]
6. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Sun S; Zhang Z; Pokrovskaia N; Chowdhury S; Jia Q; Chang E; Khakh K; Kwan R; McLaren DG; Radomski CC; Ratkay LG; Fu J; Dales NA; Winther MD
Bioorg Med Chem; 2015 Feb; 23(3):455-65. PubMed ID: 25555732
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Liu G
Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
11. Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Matter H; Zoller G; Herling AW; Sanchez-Arias JA; Philippo C; Namane C; Kohlmann M; Pfenninger A; Voss MD
Bioorg Med Chem Lett; 2013 Mar; 23(6):1817-22. PubMed ID: 23395660
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
13. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Yang SM; Tang Y; Zhang R; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6773-6. PubMed ID: 24153205
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance.
Voss MD; Beha A; Tennagels N; Tschank G; Herling AW; Quint M; Gerl M; Metz-Weidmann C; Haun G; Korn M
Diabetologia; 2005 Dec; 48(12):2622-30. PubMed ID: 16284748
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
Liu G; Lynch JK; Freeman J; Liu B; Xin Z; Zhao H; Serby MD; Kym PR; Suhar TS; Smith HT; Cao N; Yang R; Janis RS; Krauser JA; Cepa SP; Beno DW; Sham HL; Collins CA; Surowy TK; Camp HS
J Med Chem; 2007 Jun; 50(13):3086-100. PubMed ID: 17530838
[TBL] [Abstract][Full Text] [Related]
16. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
17. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
18. Sterculic oil, a natural inhibitor of SCD1, improves the metabolic state of obese OLETF rats.
Ortinau LC; Nickelson KJ; Stromsdorfer KL; Naik CY; Pickering RT; Haynes RA; Fritsche KL; Perfield JW
Obesity (Silver Spring); 2013 Feb; 21(2):344-52. PubMed ID: 23404766
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Imamura K; Tomita N; Kawakita Y; Ito Y; Ono K; Nii N; Miyazaki T; Yonemori K; Tawada M; Sumi H; Satoh Y; Yamamoto Y; Miyahisa I; Sasaki M; Satomi Y; Hirayama M; Nishigaki R; Maezaki H
Bioorg Med Chem; 2017 Jul; 25(14):3768-3779. PubMed ID: 28571972
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro.
Kim E; Lee JH; Ntambi JM; Hyun CK
Eur J Pharmacol; 2011 Dec; 672(1-3):38-44. PubMed ID: 21970804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
